Paliperidone
Brand: Invega (US/EU) / Palidon (IN) / Invega Sustenna (LAI)
Psychiatric
Atypical antipsychotic (D2/5HT2A blocker)
Pharmacokinetics
| Half-life | 23 hours |
| Tmax | 1.5 h |
| Bioavailability | 28 % (approx) |
| Protein Binding | 74 % |
| Volume of Distribution | 1.2 L/kg (approx) |
| Clearance Route | renal |
| Active Metabolites | no |
| Notes | Renal excretion major; adjust dose in CKD. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Extrapyramidal symptoms, hyperprolactinemia, weight gain, akathisia
Contraindications:
Known hypersensitivity
Precautions:
Dose reduction in renal impairment; caution with QT prolonging drugs